Assessment of mechanisms driving non-linear dose-response relationships in genotoxicity testing

Mutation Research - Reviews in Mutation Research

Volumn 763, Issue , 2015, Pages 181-201

  Guerard M ^a   Baum, M ^b   Bitsch, A ^c   Eisenbrand, G ^d   Elhajouji, A ^e   Epe, B ^f   Habermeyer, M ^d   Kaina, B ^g   Martus, H J ^e   Pfuhler, S ^h   Schmitz, C ⁱ   Sutter, A ^j   Thomas, A D ^g   Ziemann, C ^c   Froetschl, R ^k  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BASF SE   (Germany)

^c FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^d University of Koblenz Landau   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h PROCTER AND GAMBLE COMPANY   (United States)

ⁱ DLAC Dienstleistungsagentur Chemie GmbH   (Germany)

^j BAYER PHARMA AG   (Germany)

^k Ferderal Inst for Drugs Medical Devises Bundesinstitut fur Arzneimittel Medizinprodukte (BfArM) Genetic and Reproductive Toxicology   (Germany)

more..

Author keywords

DNA damage; Genetic toxicology; Non linear dose response; Threshold

Indexed keywords

ALKYLATING AGENT; ANEUGEN; DNA TOPOISOMERASE INHIBITOR; NANOPARTICLE; NUCLEOSIDE ANALOG; OXIDIZING AGENT; MUTAGENIC AGENT; NUCLEOSIDE; PARTICULATE MATTER;

DNA REPAIR; GENE INACTIVATION; GENOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; NON LINEAR DOSE RESPONSE; NONHUMAN; NONLINEAR SYSTEM; PARTICULATE MATTER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICOLOGICAL PARAMETERS; TRANSGENIC ORGANISM; ADVERSE EFFECTS; ANIMAL; CHEMICAL MODEL; DNA DAMAGE; DOSE RESPONSE; HUMAN; MUTAGEN TESTING; PROCEDURES;

ALKYLATING AGENTS; ANEUGENS; ANIMALS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, CHEMICAL; MUTAGENICITY TESTS; MUTAGENS; NUCLEOSIDES; OXIDANTS; PARTICULATE MATTER; RISK ASSESSMENT; TOPOISOMERASE INHIBITORS;

EID: 84925077549     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2014.11.001     Document Type: Review

References (211)

1. Crebelli R. Threshold-mediated mechanisms in mutagenesis: implications in the classification and regulation of chemical mutagens. Mutat. Res. 2000, 464:129-135.
2. Calabrese E.J. The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch. Toxicol. 2009, 83:203-225.
3. Gollapudi B.B., Johnson G.E., Hernandez L.G., Pottenger L.H., Dearfield K.L., Jeffrey A.M., Julien E., Kim J.H., Lovell D.P., Macgregor J.T., Moore M.M., van Benthem J., White P.A., Zeiger E., Thybaud V. Quantitative approaches for assessing dose-response relationships in genetic toxicology studies. Environ. Mol. Mutagen. 2013, 54:8-18.
4. Elhajouji A., Van Hummelen P., Kirsch-Volders M. Indications for a threshold of chemically-induced aneuploidy in vitro in human lymphocytes. Environ. Mol. Mutagen. 1995, 26:292-304.
5. Swenberg J.A., Fryar-Tita E., Jeong Y.C., Boysen G., Starr T., Walker V.E., Albertini R.J. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem. Res. Toxicol. 2008, 21:253-265.
6. Cohen S.M., Robinson D., MacDonald J. Alternative models for carcinogenicity testing. Toxicol. Sci. 2001, 64:14-19.
7. Lambert I.B., Singer T.M., Boucher S.E., Douglas G.R. Detailed review of transgenic rodent mutation assays. Mutat. Res. 2005, 590:1-280.
8. Carreras Puigvert J., von Stechow L., Siddappa R., Pines A., Bahjat M., Haazen L.C., Olsen J.V., Vrieling H., Meerman J.H., Mullenders L.H., van de Water B., Danen E.H. Systems biology approach identifies the kinase Csnk1a1 as a regulator of the DNA damage response in embryonic stem cells. Sci. Signal. 2013, 6:ra5.
9. von Stechow L., van de Water B., Danen E.H. Unraveling DNA damage response-signaling networks through systems approaches. Arch. Toxicol. 2013, 87:1635-1648.
10. Framework for Determining a Mutagenic Mode of Action for Carcinogenicity: Using EPA's 2005 Cancer Guidelines and Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens, (2007). http://epa.gov/osa/mmoaframework/pdfs/MMOA-ERD-FINAL-83007.pdf.
11. Slob W., Setzer R.W. Shape and steepness of toxicological dose-response relationships of continuous endpoints. Crit. Rev. Toxicol. 2014, 44(3):270-297. Epub 2013 Nov 19. Review. PMID: 24252121. 10.3109/10408444.2013.853726.
12. Lutz W.K. Dose-response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes. Mutat. Res. 1998, 405:117-124.
13. MacGregor J.T., Frötschl R., White P.A., Crump K.S., Eastmond D.A., Fukushima S., Guérard M., Hayashi M., Soeteman-Hernandez L., Kasamatsu T., Levy D., Morita T., Müller L., Schoeny R., Schuler M.J., Thybaud V., Johnson G.E. IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure-response relationships and points of departure (PoDs). Mutat. Res. 2014, (in press). 10.1016/j.mrgentox.2014.09.011.
14. Lutz W.K. The Viracept (nelfinavir)-ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?. Toxicol. Lett. 2009, 190:239-242.
15. Johnson G.E., Soeteman-Hernandez L.G., Gollapudi B.B., Bodger O.G., Dearfield K.L., Heflich R.H., Hixon J.G., Lovell D.P., Macgregor J.T., Pottenger L.H., Thompson C.M., Abraham L., Thybaud V., Tanir J.Y., Zeiger E., van Benthem J., White P.A. Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. Environ. Mol. Mutagen. 2014, 55(8):609-623. Epub 2014 May 6. 10.1002/em.21870.
16. Vogel E.W., Natarajan A.T. The relation between reaction kinetics and mutagenic action of mono-functional alkylating agents in higher eukaryotic systems: II. Total and partial sex-chromosome loss in drosophila. Mutat. Res. 1979, 62:101-123.
17. Vogel E.W., Natarajan A.T. The relation between reaction kinetics and mutagenic action of mono-functional alkylating agents in higher eukaryotic systems I. Recessive lethal mutations and translocations in Drosophila. Mutat. Res. 1979, 62:51-100.
18. Natarajan A.T., Simons J.W.I.M., Vogel E.W., Van Zeeland A.A. Relationship between cell killing, chromosomal aberrations, sister-chromatid exchanges and point mutations induced by monofunctional alkylating agents in Chinese hamster cells a correlation with different ethylation products in DNA. Mutat. Res. 1984, 128:31-40.
19. Van Zeeland a.a., Mohn G.R., Mullenders L.H., Natarajan a.T., Nivard M., Simons J.W., Venema J., Vogel E.W., Vrieling H., Zdzienicka M.Z. Relationship between DNA-adduct formation. DNA Repair 1989, 223-228. (mutation frequency and mutation spectra).
20. Jenkins G.J.S., Doak S.H., Johnson G.E., Quick E., Waters E.M., Parry J.M. Do dose response thresholds exist for genotoxic alkylating agents?. Mutagenesis 2005, 20:389-398.
21. Loveless A. Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. Nature 1969, 223:206-207.
22. Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007, 6:1079-1099.
23. Boysen G., Pachkowski B.F., Nakamura J., Swenberg J.A. The formation and biological significance of N7-Gunaine adducts. Mutat. Res. 2009, 678(2):76-94. Epub 2009 May 22. 10.1016/j.mrgentox.2009.05.006.
24. Doak S.H., Jenkins G.J.S., Johnson G.E., Quick E., Parry E.M., Parry J.M. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res. 2007, 67:3904-3911.
25. Johnson G.E., Doak S.H., Griffiths S.M., Quick E.L., Skibinski D.O.F., Zaïr Z.M., Jenkins G.J. Non-linear dose-response of DNA-reactive genotoxins: recommendations for data analysis. Mutat. Res. 2009, 678:95-100.
26. Gocke E., Müller L. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU. Mutat. Res. 2009, 678:101-107.
27. Gocke E., Ballantyne M., Whitwell J., Müller L. MNT and Muta TM Mouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU. Toxicol. Lett. 2009, 190(3):286-297. Epub 2009 Apr 1. 10.1016/j.toxlet.2009.03.021.
28. Christmann M., Kaina B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res. 2013, 41:8403-8420.
29. Dobo K.L., Fiedler R.D., Gunther W.C., Thiffeault C.J., Cammerer Z., Coffing S.L., Shutsky T., Schuler M. Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats. Mutat. Res. 2011, 725:13-21.
30. Dobrovolsky V.N., Miura D., Heflich R.H., Dertinger S.D. The in vivo pig-a gene mutation assay, a potential tool for regulatory safety assessment. Environ. Mol. Mutagen. 2010, 51(8-9):825-835. 10.1002/em.20627.
31. Donovan P., Smith G. Mutagenicity of N-ethyl-N-nitrosourea, N-methyl-N-nitrosourea, methyl methanesulfonate and ethyl methanesulfonate in the developing Syrian hamster fetus. Mutat. Res. 2010, 699:55-57.
32. Beranek D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res. 1990, 231:11-30.
33. Pottenger L.H., Schisler M.R., Zhang F., Bartels M.J., Fontaine D.D., McFadden L.G., Gollapudi Bhaskar B. Dose-response and operational thresholds/NOAELs for in vitro mutagenic effects from DNA-reactive mutagens, MMS and MNU. Mutat. Res. 2009, 678:138-147.
34. Bryce S.M., Avlasevich S.L., Bemis J.C., Phonethepswath S., Dertinger S.D. Miniaturized flow cytometric in vitro micronucleus assay represents an efficient tool for comprehensively characterizing genotoxicity dose-response relationships. Mutat. Res. 2010, 703:191-199. (Genetic Toxicology and Environmental Mutagenesis).
35. Jenssen D., Ramel C. Relationship between chemical damage of DNA and mutations in Mammalian cells. I. Dose-response curves for the induction of 6-thioguanine-resistant mutants by low doses of monofunctional alkylating agents, x-raus and UV radiation in V79 Chinese hamster cel. Mutat. Res. 1980, 73:339-347.
36. Bartsch H., Terracini B., Malaveille C., Tomatis L., Wahrendorf J., Brun G., Dodet B. Quantitative comparison of carcinogenicity, mutagenicity and electrophilicity of 10 direct-acting alkylating agents and of the initial O6:7-alkylguanine ratio in DNA with carcinogenic potency in rodents. Mutat. Res. 1983, 110:181-219.
37. Chapman K.E., Thomas A.D., Wills J.W., Pfuhler S., Doak S.H., Jenkins G.J.S. Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis 2014, 29(3):165-175. Epub 2014 Mar 27. 10.1093/mutage/geu011.
38. Speit G., Autrup H., Crebelli R., Henderson L., Kirsch-Volders M., Madle S., Parry J.M., Sarrif a.M., Vrijhof H. Thresholds in genetic toxicology-concluding remarks. Mutat. Res. 2000, 464:149-153.
39. Johnson G.E., Zair Z., Bodger O.G., Lewis P.D., Rees B.J., Verma J.R., Thomas A.D., Doak S.H., Jenkins G.J.S. Investigating mechanisms for non-linear genotoxic responses, and analysing their effects in binary combination. Genes Environ. 2012, 34:179-185.
40. Kaina B., Fritz G., Coquerelle T. Contribution of O6-alkylguanine and N-alkylpurines to the formation of sister chromatid exchanges, chromosomal aberrations, and gene mutations: new insights gained from studies of genetically engineered mammalian cell lines. Environ. Mol. Mutagen. 1993, 22:283-292.
41. Kaina B., Fritz G., Ochs K., Haas S., Grombacher T., Gregel C.M., Becker K. Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms. Mutat. Res. 1998, 405(2):179-191.
42. Becker K., Thomas A.D., Kaina B. Brief communication does increase in DNA repair allow skin tumor experiments with MGMT-overexpressing mice. Environ. Mol. Mutagen. 2014, 55:145-150.
43. Sharma V., Collins L.B., Clement J.M., Zhang Z., Nakamura J., Swenberg J.A. Molecular dosimetry of endogenous and exogenous O(6)-methyl-dG and N7-methyl-G adducts following low dose [D3]-methylnitrosourea exposures in cultured human cells. Chem. Res. Toxicol. 2014, 27:480-482.
44. Vidal A., Abril N., Pueyo C. DNA repair by Ogt alkyltransferase influences EMS mutational specificity. Carcinogenesis 1995, 16:817-821.
45. Tang L., Guerard M., Zeller A. Quantitative assessment of the dose-response of alkylating agents in DNA repair proficient and deficient ames tester strains. Environ. Mol. Mutagen. 2014, 55(1):15-23. Epub 2013 Nov 23. 10.1002/em.21825.
46. Zaïr Z.M., Jenkins G.J., Doak S.H., Singh R., Brown K., Johnson G.E. N-methylpurine DNA glycosylase plays a pivotal role in the threshold response of ethyl methanesulfonate-induced chromosome damage. Toxicol. Sci. 2011, 119:346-358. (an official journal of the Society of Toxicology).
47. Engelward B.P., Dreslin A., Christensen J., Huszar D., Kurahara C., Samson L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J. 1996, 15:945-952.
48. Roth R.B., Samson L.D. 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res. 2002, 62:656-660.
49. Coquerelle T., Dosch J., Kaina B. Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents-a case of imbalanced DNA repair. Mutat. Res./DNA Repair 1995, 336:9-17.
50. Thomas A.D., Jenkins G.J.S., Kaina B., Bodger O.G., Tomaszowski K.-H., Lewis P.D., Doak S.H., Johnson G.E. Influence of DNA repair on nonlinear dose-responses for mutation. Toxicol. Sci. 2013, 132:87-95. (an official journal of the Society of Toxicology).
51. Cao X., Mittelstaedt R.A., Pearce M.G., Allen B.C., Soeteman-Hernandez L.G., Johnson G.E., Bigger C.A., Heflich R.H. Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice. Environ. Mol. Mutagen. 2014, 55:385-399.
52. Bronstein S.M., Cochrane J.E., Craft T.R., Swenberg J.A., Skopek T.R. Toxicity, mutagenicity, and mutational spectra of N-ethyl-N-nitrosourea in human cell lines with different DNA repair phenotypes. Cancer Res. 1991, 51(19):5188-5197.
53. Capucci M.S., Hoffmann M.E., De Groot a., Natarajan a.T. Streptozotocin-induced toxicity in CHO-9 and V79 cells. Environ. Mol. Mutagen. 1995, 26:72-78.
54. Suter W., Brennand J., McMillan S., Fox M. Relative mutagenicity of antineoplastic drugs and other alkylating agents in V79 Chinese hamster cells, independence of cytotoxic and mutagenic responses. Mutat. Res. 1980, 73:171-181.
55. Roos W.P., Christmann M., Fraser S.T., Kaina B. Mouse embryonic stem cells are hypersensitive to apoptosis triggered by the DNA damage O(6)-methylguanine due to high E2F1 regulated mismatch repair. Cell Death Diff. 2007, 14:1422-1432.
56. Epe B. Role of endogenous oxidative DNA damage in carcinogenesis: what can we learn from repair-deficient mice?. Biol. Chem. 2002, 383:467-475.
57. Seager A.L., Shah U.K., Mikhail J.M., Nelson B.C., Marquis B.J., Doak S.H., Johnson G.E., Griffiths S.M., Carmichael P.L., Scott S.J., Scott A.D., Jenkins G.J. Pro-oxidant induced DNA damage in human lymphoblastoid cells: homeostatic mechanisms of genotoxic tolerance. Toxicol. Sci. 2012, 128:387-397.
58. Platel A., Nesslany F., Gervais V., Marzin D. Study of oxidative DNA damage in TK6 human lymphoblastoid cells by use of the in vitro micronucleus test: determination of no-observed-effect levels. Mutat. Res. 2009, 678:30-37.
59. Platel A., Gervais V., Sajot N., Nesslany F., Marzin D., Claude N. Study of gene expression profiles in TK6 human cells exposed to DNA-oxidizing agents. Mutat. Res. 2010, 689:21-49.
60. Platel A., Nesslany F., Gervais V., Claude N., Marzin D. Study of oxidative DNA damage in TK6 human lymphoblastoid cells by use of the thymidine kinase gene-mutation assay and the in vitro modified comet assay: determination of no-observed-genotoxic-effect-levels. Mutat. Res. 2011, 726:151-159.
61. Spassova M.A., Miller D.J., Eastmond D.A., Nikolova N.S., Vulimiri S.V., Caldwell J., Chen C., White P.D. Dose-response analysis of bromate-induced DNA damage and mutagenicity is consistent with low-dose linear, nonthreshold processes. Environ. Mol. Mutagen. 2013, 54:19-35.
62. DeAngelo A.B., George M.H., Kilburn S.R., Moore T.M., Wolf D.C. Carcinogenicity of potassium bromate administered in the drinking water to male B6C3F1 mice and F344/N rats. Toxicol. Pathol. 1998, 26:587-594.
63. Ballmaier D., Epe B. Oxidative DNA damage induced by potassium bromate under cell-free conditions and in mammalian cells. Carcinogenesis 1995, 16:335-342.
64. Ballmaier D., Epe B. DNA damage by bromate: mechanism and consequences. Toxicology 2006, 221:166-171.
65. Moore M.M., Chen T. Mutagenicity of bromate: implications for cancer risk assessment. Toxicology 2006, 221:190-196.
66. Allen J.W., Collins B.W., Lori A., Afshari A.J., George M.H., DeAngelo A.B., Fuscoe J.C. Erythrocyte and spermatid micronucleus analyses in mice chronically exposed to potassium bromate in drinking water. Environ. Mol. Mutagen. 2000, 36:250-253.
67. Awogi T., Murata K., Uejima M., Kuwahara T., Asanami S., Shimono K., Morita T. Induction of micronucleated reticulocytes by potassium bromate and potassium chromate in CD-1 male mice. Mutat. Res. 1992, 278:181-185.
68. Yamaguchi T., Wei M., Hagihara N., Omori M., Wanibuchi H., Fukushima S. Lack of mutagenic and toxic effects of low dose potassium bromate on kidneys in the Big Blue rat. Mutat. Res. 2008, 652:1-11.
69. Umemura T., Kanki K., Kuroiwa Y., Ishii Y., Okano K., Nohmi T., Nishikawa A., Hirose M. In vivo mutagenicity and initiation following oxidative DNA lesion in the kidneys of rats given potassium bromate. Cancer Sci. 2006, 97:829-835.
70. Sun B., Ross S.M., Trask O.J., Carmichael P.L., Dent M., White A., Andersen M.E., Clewell R.A. Assessing dose-dependent differences in DNA-damage, p53 response and genotoxicity for quercetin and curcumin. Toxicol. In Vitro 2013, 27:1877-1887. (an international journal published in association with BIBRA).
71. Klungland A., Rosewell I., Hollenbach S., Larsen E., Daly G., Epe B., Seeberg E., Lindahl T., Barnes D.E. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13300-13305.
72. Minowa O., Arai T., Hirano M., Monden Y., Nakai S., Fukuda M., Itoh M., Takano H., Hippou Y., Aburatani H., Masumura K., Nohmi T., Nishimura S., Noda T. Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:4156-4161.
73. Osterod M., Hollenbach S., Hengstler J.G., Barnes D.E., Lindahl T., Epe B. Age-related and tissue-specific accumulation of oxidative DNA base damage in 7,8-dihydro-8-oxoguanine-DNA glycosylase (Ogg1) deficient mice. Carcinogenesis 2001, 22:1459-1463.
74. Comparative analysis of baseline 8-oxo-7,8-dihydroguanine in mammalian cell DNA, by different methods in different laboratories: an approach to consensus. Carcinogenesis 2002, 23:2129-2133.
75. Trapp C., Schwarz M., Epe B. The peroxisome proliferator WY-14,643 promotes hepatocarcinogenesis caused by endogenously generated oxidative DNA base modifications in repair-deficient Csbm/m/Ogg1-/- mice. Cancer Res. 2007, 67:5156-5161.
76. Schins R.P., Knaapen A.M. Genotoxicity of poorly soluble particles. Inhalation Toxicol. 2007, 19(Suppl 1):189-198.
77. Knaapen A.M., Borm P.J., Albrecht C., Schins R.P. Inhaled particles and lung cancer. Part A: Mechanisms. Int. J. Cancer 2004, 109:799-809.
78. Huang S.X., Jaurand M.C., Kamp D.W., Whysner J., Hei T.K. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J. Toxicol. Environ. Health. B, Crit. Rev. 2011, 14:179-245.
79. Daniel L.N., Mao Y., Williams A.O., Saffiotti U. Direct interaction between crystalline silica and DNA-a proposed model for silica carcinogenesis. Scand. J. Work Environ. Health 1995, 21(Suppl 2):22-26.
80. Jaurand M.C. Mechanisms of fiber-induced genotoxicity. Environ. Health Perspect. 1997, 105(Suppl 5):1073-1084.
81. ECETOC TR122: Poorly soluble particles/lung overload (2014), http://www.ecetoc.org/publications.
82. Oberdorster G. Toxicokinetics and effects of fibrous and nonfibrous particles. Inhalation Toxicol. 2002, 14:29-56.
83. Brown R.C., Bellmann B., Muhle H., Ernst H., Pohlmann G.-, Sebastien P. Subchronic studies on man-made vitreous fibres: toxicity results. Ann. Occup. Hyg. 2002, 46:102-104.
84. Moolgavkar S.H., Brown R.C., Turim J. Biopersistence, fiber length, and cancer risk assessment for inhaled fibers. Inhalation Toxicol. 2001, 13:755-772.
85. Hesterberg T.W., Anderson R., Bernstein D.M., Bunn W.B., Chase G.A., Jankousky A.L., Marsh G.M., McClellan R.O. Product stewardship and science: safe manufacture and use of fiber glass. Regul. Toxicol. Pharm.: RTP 2012, 62:257-277.
86. Bernstein D., Castranova V., Donaldson K., Fubini B., Hadley J., Hesterberg T., Kane A., Lai D., McConnell E.E., Muhle H., Oberdorster G., Olin S., Warheit D.B. Testing of fibrous particles: short-term assays and strategies. Inhalation Toxicol. 2005, 17:497-537.
87. Mossman B.T., Lippmann M., Hesterberg T.W., Kelsey K.T., Barchowsky A., Bonner J.C. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J. Toxicol. Environ. Health. B, Crit. Rev. 2011, 14:76-121.
88. Vu V., Barrett J.C., Roycroft J., Schuman L., Dankovic D., Bbaro P., Martonen T., Pepelko W., Lai D. Chronic inhalation toxicity and carcinogenicity testing of respirable fibrous particles. Workshop Rep., Regul. Toxicol. Pharmacol.: RTP 1996, 24:202-212.
89. Comission G.M. Allgemeiner Staubgrenzwert (A-Fraktion) (Granuläre biobeständige Stäube (GBS)) MAK Value Documentation in German language 2012, 53. Published Online: 20 DEC 2012. 10.1002/3527600418.mb0230stwd0053.
90. Schins R.P. Mechanisms of genotoxicity of particles and fibers. Inhalation Toxicol. 2002, 14:57-78.
91. Moller P., Danielsen P.H., Jantzen K., Roursgaard M., Loft S. Oxidatively damaged DNA in animals exposed to particles. Crit. Rev. Toxicol. 2013, 43:96-118.
92. I.W.G.o.t.E.o.C.R.t. Humans: arsenic, metals, fibres, and dusts. IARC Monogr. Eval. Carcinog. Risks Hum. 2012, 100(Pt C):11-465.
93. Muhle H., Pott F. Asbestos as reference material for fibre-induced cancer. Int. Arch. Occup. Environ. Health 2000, 73(Suppl):S53-S59.
94. Rittinghausen S., Bellmann B., Creutzenberg O., Ernst H., Kolling A., Mangelsdorf I., Kellner R., Beneke S., Ziemann C. Evaluation of immunohistochemical markers to detect the genotoxic mode of action of fine and ultrafine dusts in rat lungs. Toxicology 2013, 303:177-186.
95. Oesch F., Landsiedel R. Genotoxicity investigations on nanomaterials. Arch. Toxicol. 2012, 86:985-994.
96. Kumar A., Dhawan A. Genotoxic and carcinogenic potential of engineered nanoparticles: an update. Arch. Toxicol. 2013, 87:1883-1900.
97. C.P.a.t.E.C. Committee on Mutagenicity of Chemicals in Food Statement on Genotoxicity Assessment of Nanomaterials and Experimental Considerations. MUT/2012/04, DRAFT (3rd) 2014.
98. Magdolenova Z., Collins A., Kumar A., Dhawan A., Stone V., Dusinska M. Mechanisms of genotoxicity. A review of in vitro and in vivo studies with engineered nanoparticles. Nanotoxicology 2014, 8:233-278.
99. Doak S.H., Manshian B., Jenkins G.J., Singh N. In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines. Mutat. Res. 2012, 745:104-111.
100. Pfuhler S., Elespuru R., Aardema M.J., Doak S.H., Maria Donner E., Honma M., Kirsch-Volders M., Landsiedel R., Manjanatha M., Singer T., Kim J.H. Genotoxicity of nanomaterials: refining strategies and tests for hazard identification. Environ. Mol. Mutagen. 2013, 54:229-239.
101. OECD Draft Guidance Document on the Use of OECD Test Guidelines on Genotoxicity Testing for Manufactured Nanomaterials 2014, http://www.oecd.org/env/ehs/testing/Draft_GD_nano_and_genotox_rev2.pdf.
102. Bhattacharya K., Davoren M., Boertz J., Schins R.P., Hoffmann E., Dopp E. Titanium dioxide nanoparticles induce oxidative stress and DNA-adduct formation but not DNA-breakage in human lung cells. Part. Fibre Toxicol. 2009, 6:17.
103. 2 nanoparticles. Exp. Cell Res. 2005, 305:51-62.
104. Shukla R.K., Sharma V., Pandey A.K., Singh S., Sultana S., Dhawan A. ROS-mediated genotoxicity induced by titanium dioxide nanoparticles in human epidermal cells. Toxicol. In Vitro 2011, 25:231-241. (an international journal published in association with BIBRA).
105. Donaldson K., Poland C.A., Schins R.P. Possible genotoxic mechanisms of nanoparticles: criteria for improved test strategies. Nanotoxicology 2010, 4:414-420.
106. Xu A., Chai Y., Nohmi T., Hei T.K. Genotoxic responses to titanium dioxide nanoparticles and fullerene in gpt delta transgenic MEF cells. Part. Fibre Toxicol. 2009, 6:3.
107. Siegrist K.J., Reynolds S.H., Kashon M.L., Lowry D.T., Dong C., Hubbs A.F., Young S.H., Salisbury J.L., Porter D.W., Benkovic S.A., McCawley M., Keane M.J., Mastovich J.T., Bunker K.L., Cena L.G., Sparrow M.C., Sturgeon J.L., Dinu C.Z., Sargent L.M. Genotoxicity of multi-walled carbon nanotubes at occupationally relevant doses. Part. Fibre Toxicol. 2014, 11:6.
108. Dinu C.Z., Bale S.S., Zhu G., Dordick J.S. Tubulin encapsulation of carbon nanotubes into functional hybrid assemblies. Small 2009, 5:310-315.
109. Sargent L.M., Shvedova A.A., Hubbs A.F., Salisbury J.L., Benkovic S.A., Kashon M.L., Lowry D.T., Murray A.R., Kisin E.R., Friend S., McKinstry K.T., Battelli L., Reynolds S.H. Induction of aneuploidy by single-walled carbon nanotubes. Environ. Mol. Mutagen. 2009, 50:708-717.
110. Sargent L.M., Reynolds S.H., Castranova V. Potential pulmonary effects of engineered carbon nanotubes: in vitro genotoxic effects. Nanotoxicology 2010, 4:396-408.
111. Doak S.H., Pfuhler S. Nanotoxicology. Preface, Mutat. Res. 2012, 745:1-3.
112. Borm P.J., Tran L., Donaldson K. The carcinogenic action of crystalline silica: a review of the evidence supporting secondary inflammation-driven genotoxicity as a principal mechanism. Crit. Rev. Toxicol. 2011, 41:756-770.
113. Downs T.R., Crosby M.E., Hu T., Kumar S., Sullivan A., Sarlo K., Reeder B., Lynch M., Wagner M., Mills T., Pfuhler S. Silica nanoparticles administered at the maximum tolerated dose induce genotoxic effects through an inflammatory reaction while gold nanoparticles do not. Mutat. Res. 2012, 745:38-50.
114. Magdolenova Z., Drlickova M., Henjum K., Runden-Pran E., Tulinska J., Bilanicova D., Pojana G., Kazimirova A., Barancokova M., Kuricova M., Liskova A., Staruchova M., Ciampor F., Vavra I., Lorenzo Y., Collins A., Rinna A., Fjellsbo L., Volkovova K., Marcomini A., Amiry-Moghaddam M., Dusinska M. Coating-dependent induction of cytotoxicity and genotoxicity of iron oxide nanoparticles. Nanotoxicology 2013, 1-13. Ahead of Print. 10.3109/17435390.2013.847505.
115. Mendoza A., Torres-Hernandez J.A., Ault J.G., Pedersen-Lane J.H., Gao D., Lawrence D.A. Silica nanoparticles induce oxidative stress and inflammation of human peripheral blood mononuclear cells. Cell Stress Chaperones 2014, 19(6):777-790. Epub 2014 Feb 18. 10.1007/s12192-014-0502-y.
116. Wang C., Wu C., Zhou X., Han T., Xin X., Wu J., Zhang J., Guo S. Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots. Sci. Rep. 2013, 3:2852.
117. Wutzler P., Thust R. Genetic risks of antiviral nucleoside analogues-a survey. Antiviral Res. 2001, 49:55-74.
118. Ewald B., Sampath D., Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008, 27:6522-6537.
119. Olivero O.A. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ. Mol. Mutagen. 2007, 48:215-223.
120. C.P.A.T.E Committee on Mutagenicity of Chemicals in Food Guidance Statement: Thresholds for In Vivo Mutagens 2010, https://www.gov.uk/government/publications/assessment-of-thresholds-for-in-vitro-mutagens.
121. Muller L., Kasper P. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res. 2000, 464:19-34.
122. Suter W., Plappert-Helbig U., Glowienke S., Poetter-Locher F., Staedtler F., Racine R., Martus H.J. Induction of gene mutations by 5-(2-chloroethyl)-2'-deoxyuridine (CEDU), an antiviral pyrimidine nucleoside analogue. Mutat. Res. 2004, 568:195-209.
123. Zeller A., Koenig J., Schmitt G., Singer T., Guerard M. Genotoxicity profile of azidothymidine in vitro. Toxicol. Sci. 2013, 135:317-327. (an official journal of the Society of Toxicology).
124. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113:173-215.
125. Lutz W.K., Lutz R.W. Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data. Mutat. Res. 2009, 678(2):118-122. Epub 2009 May 27. 10.1016/j.mrgentox.2009.05.010.
126. Phillips M.D., Nascimbeni B., Tice R.R., Shelby M.D. Induction of micronuclei in mouse bone marrow cells: an evaluation of nucleoside analogues used in the treatment of AIDS. Environ. Mol. Mutagen. 1991, 18:168-183.
127. Guerard M., Koenig J., Festag M., Dertinger S.D., Singer T., Schmitt G., Zeller A. Assessment of the genotoxic potential of azidothymidine in the comet, micronucleus, and Pig-a assay. Toxicol. Sci. 2013, 135:309-316. (an official journal of the Society of Toxicology).
128. Haynes P., Lambert T.R., Mitchell I.D. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat. Res. 1996, 369:65-74.
129. Fortune J.M., Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 2000, 64:221-253.
130. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 2009, 109:2894-2902.
131. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65:635-692.
132. Yang L., Wold M.S., Li J.J., Kelly T.J., Liu L.F. Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:950-954.
133. Demeret C., Vassetzky Y., Mechali M. Chromatin remodelling and DNA replication: from nucleosomes to loop domains. Oncogene 2001, 20:3086-3093.
134. Backer L.C., Allen J.W., Harrington-Brock K., Campbell J.A., DeMarini D.M., Doerr C.L., Howard D.R., Kligerman A.D., Moore M.M. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Mutagenesis 1990, 5:541-547.
135. Pommier Y., Leo E., Zhang H., Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17:421-433.
136. Lynch A., Harvey J., Aylott M., Nicholas E., Burman M., Siddiqui A., Walker S., Rees R. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 2003, 18:345-353.
137. Smart D.J. Genotoxicity of topoisomerase II inhibitors: an anti-infective perspective. Toxicology 2008, 254:192-198.
138. Smart D.J., Halicka H.D., Schmuck G., Traganos F., Darzynkiewicz Z., Williams G.M. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res. 2008, 641:43-47.
139. Morais Cabral J.H., Jackson A.P., Smith C.V., Shikotra N., Maxwell A., Liddington R.C. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 1997, 388:903-906.
140. Lenz J., Lemcke T., Heisig P., Torda A. Characterization of the quinolone-gyrase-interaction using docking, molecular-dynamics and site-directed mutagenesis, from computational biophysics to systems biology (CBSB08). Proceedings of the NIC Workshop 2008 2008, 289-292. (NIC Series 40). U.H.E. Hansmann, J.H. Meinke, S. Mohanty, W. Nadler, O. Zimmermann (Eds.).
141. Bromberg K.D., Burgin A.B., Osheroff N. A two-drug model for etoposide action against human topoisomerase IIalpha. J. Biol. Chem. 2003, 278:7406-7412.
142. Santivasi W.L., Xia F. The role and clinical significance of DNA damage response and repair pathways in primary brain tumors. Cell Biosci. 2013, 3:10.
143. Albertini S., Chetelat A.A., Miller B., Muster W., Pujadas E., Strobel R., Gocke E. Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis 1995, 10:343-351.
144. Hayasaki Y., Itoh S., Kato M., Furuhama K. Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101. Toxicol. In Vitro 2006, 20:342-346. (an international journal published in association with BIBRA).
145. Shimada H., Itoh S. Effects of new quinolone antibacterial agents on mammalian chromosomes. J. Toxicol. Environ. Health 1996, 47:115-123.
146. Herbold B.A., Brendler-Schwaab S.Y., Ahr H.J. Ciprofloxacin: in vivo genotoxicity studies. Mutat. Res. 2001, 498:193-205.
147. Singh A.C., Kumar M., Jha A.M. Genotoxicity of lomefloxacin-an antibacterial drug in somatic and germ cells of Swiss albino mice in vivo. Mutat. Res. 2003, 535:35-42.
148. Li Z., Sun B., Clewell R.A., Adeleye Y., Andersen M.E., Zhang Q. Dose-response modeling of etoposide-induced DNA damage response. Toxicol. Sci. 2014, 137:371-384.
149. Parry E.M., Parry J.M., Corso C., Doherty A., Haddad F., Hermine T.F., Johnson G., Kayani M., Quick E., Warr T., Williamson J. Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagenesis 2002, 17:509-521.
150. Kirsch-Volders M., Sofuni T., Aardema C., Albertini S., Eastmond D., Fenech M., Ishidate M., Kirchner S., Lorge E., Morita T., Norppa H., Surralles J., Vanhauwaert A., Wakata A. Report from the in vitro micronucleus assay working group. Mutat. Res. 2003, 540:153-163. (Genetic Toxicology and Environmental Mutagenesis).
151. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
152. Elhajouji A., Lukamowicz M., Cammerer Z., Kirsch-Volders M. Potential thresholds for genotoxic effects by micronucleus scoring. Mutagenesis 2011, 26:199-204.
153. Elhajouji A., Tibaldi F., Kirsch-Volders M. Indication for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes. Mutagenesis 1997, 12:133-140.
154. Bentley K.S., Kirkland D., Murphy M., Marshall R. Evaluation of thresholds for benomyl- and carbendazim-induced aneuploidy in cultured human lymphocytes using fluorescence in situ hybridization. Mutat. Res. 2000, 464:41-51.
155. Bonacker D., Stoiber T., Bohm K.J., Unger E., Degen G.H., Thier R., Bolt H.M. Chromosomal genotoxicity of nitrobenzene and benzonitrile. Arch. Toxicol. 2004, 78:49-57.
156. Schuler M., Muehlbauer P., Guzzie P., Eastmond D.A. Noscapine hydrochloride-induced numerical aberrations in cultured human lymphocytes: a comparison of FISH detection methods and multiple end-points. Mutagenesis 2003, 18:235-242.
157. Davies A., Doherty A., Wilson A., O'Donovan M. An investigation into non-disjunction with aneugenic chemicals. Mutagenesis 2012, 27:789-816.
158. Steiblen G., Orsiere T., Pallen C., Botta A., Marzin D. Comparison of the relative sensitivity of human lymphocytes and mouse splenocytes to two spindle poisons. Mutat. Res. 2005, 588:143-151.
159. Johnson G.E., Parry E.M. Mechanistic investigations of low dose exposures to the genotoxic compounds bisphenol-A and rotenone. Mutat. Res. 2008, 651:56-63.
160. Eichenlaub-Ritter U., Shen Y., Tinneberg H.R. Manipulation of the oocyte: possible damage to the spindle apparatus. Reprod. Biomed. Online 2002, 5:117-124.
161. Seiler J.P. The mutagenicity of benzimidazole and benzimidazole derivatives. VI. Cytogenetic effects of benzimidazole derivatives in the bone marrow of the mouse and the Chinese hamster. Mutat. Res. 1976, 40:339-347.
162. Cammerer Z., Schumacher M.M., Kirsch-Volders M., Suter W., Elhajouji A. Flow cytometry peripheral blood micronucleus test in vivo: determination of potential thresholds for aneuploidy induced by spindle poisons. Environ. Mol. Mutagen. 2010, 51:278-284.
163. Tinwell H., Ashby J. Micronucleus morphology as a means to distinguish aneugens and clastogens in the mouse bone marrow micronucleus assay. Mutagenesis 1991, 6:193-198.
164. Asano N., Torous D.K., Tometsko C.R., Dertinger S.D., Morita T., Hayashi M. Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine. Mutagenesis 2006, 21:15-20.
165. Kirchner S. Kinases as Antitargets in Genotoxicity, Polypharmacology in Drug Discovery 2012, John Wiley & Sons. Inc., Hoboken, New Jersey/Canada. first ed. P. Jens-Uwe (Ed.).
166. Gollapudi P., Hasegawa L.S., Eastmond D.A. A comparative study of the aneugenic and polyploidy-inducing effects of fisetin and two model Aurora kinase inhibitors. Mutat. Res. 2014, 767:37-43. (Genetic Toxicology and Environmental Mutagenesis).
167. Le Hegarat L., Puech L., Fessard V., Poul J.M., Dragacci S. Aneugenic potential of okadaic acid revealed by the micronucleus assay combined with the FISH technique in CHO-K1 cells. Mutagenesis 2003, 18:293-298.
168. Mishima M., Tanaka K., Takeiri A., Harada A., Kubo C., Sone S., Nishimura Y., Tachibana Y., Okazaki M. Two structurally distinct inhibitors of glycogen synthase kinase 3 induced centromere positive micronuclei in human lymphoblastoid TK6 cells. Mutat. Res. 2008, 643:29-35.
169. Dahlin D.C., Miwa G.T., Lu A.Y., Nelson S.D. N-Acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:1327-1331.
170. Bergman K., Muller L., Teigen S.W. Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Mutat. Res. 1996, 349:263-288.
171. Attia S.M. Deleterious effects of reactive metabolites. Oxid. Med. Cell Longev. 2010, 3:238-253.
172. Glatt H.R., Billings R., Platt K.L., Oesch F. Improvement of the correlation of bacterial mutagenicity with carcinogenicity of benzo(a)pyrene and four of its major metabolites by activation with intact liver cells instead of cell homogenate. Cancer Res. 1981, 41:270-277.
173. Glatt H., Utesch D., Oesch F. Hepatocyte-but not S9-mediated mutagenicity correlates with the carcinogenicity of methylbenz(a)anthracenes. Polycyclic Aromatic Hydrocarbons: Mechanisms, Methods and Metabolism. Proceedings of the Eighth International Symposium 1988, 475-484. Battelle Press, Columbus, OH. M. Cooke, A.J. Dennis (Eds.).
174. Recio L., Hsie A.W. Detoxication mechanisms of benzo(a)pyrene as studied in the CHO/HPRT assay. Polycyclic Aromatic Hydrocarbons: Mechanisms, Methods and Metabolism. Proceedings of the Eighth International Symposium 1988, 761-772. Battelle Press, Columbus, OH. M. Cooke, A.J. Dennis (Eds.).
175. Singh S.V., Benson P.J., Hu X., Pal A., Xia H., Srivastava S.K., Awasthi S., Zaren H.A., Orchard J.L., Awasthi Y.C. Gender-related differences in susceptibility of A/J mouse to benzo[a]pyrene-induced pulmonary and forestomach tumorigenesis. Cancer Lett. 1998, 128:197-204.
176. Rosa R.M., Hoch N.C., Furtado G.V., Saffi J., Henriques J.A. DNA damage in tissues and organs of mice treated with diphenyl diselenide. Mutat. Res. 2007, 633:35-45.
177. Oesch F., Herrero M.E., Hengstler J.G., Lohmann M., Arand M. Metabolic detoxification: implications for thresholds. Toxicol. Pathol. 2000, 28:382-387.
178. Arand M., Herrero Plana M.E., Hengstler J.G., Lohmann M., Cronin A., Oesch F. Detoxification strategy of epoxide hydrolase-the basis for a threshold in chemical carcinogenesis. EXCLI J. 2003, 2:22-30.
179. Oesch F., Bentley P. Antibodies against homogeneous epoxide hydratase provide evidence for a single enzyme hydrating styrene oxide and benz(a)pyrene 4,5-oxide. Nature 1976, 259:53-55.
180. Ota K., Hammock B.D. Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. Science 1980, 207:1479-1481.
181. Lacourciere G.M., Armstrong R.N. The catalytic mechanism of microsomal epoxide hydrolase involves an ester intermediate. J. Am. Chem. Soc. 1993, 115:10466-10467.
182. Johnson G.E., Quick E.L., Parry E.M., Parry J.M. Metabolic influences for mutation induction curves after exposure to Sudan-1 and para red. Mutagenesis 2010, 25:327-333.
183. O'Brien J., Renwick A.G., Constable A., Dybing E., Muller D.J., Schlatter J., Slob W., Tueting W., van Benthem J., Williams G.M., Wolfreys A. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal. Food Chem. Toxicol. 2006, 44:1613-1635.
184. Benford D., Bolger P.M., Carthew P., Coulet M., DiNovi M., Leblanc J.C., Renwick A.G., Setzer W., Schlatter J., Smith B., Slob W., Williams G., Wildemann T. Application of the margin of exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem. Toxicol. 2010, 48(Suppl 1):S2-S24.
185. JECFA Evaluation of Certain Contaminants in Food: Seventy-Second Report of the Joint, FAO/WHO., Expert Committee on Food Additives 2010, World Health Organization, Geneva, Switzerland.
186. Berger F.I., Feld J., Bertow D., Eisenbrand G., Fricker G., Gerhardt N., Merz K.H., Richling E., Baum M. Biological effects of acrylamide after daily ingestion of various foods in comparison to water: a study in rats. Mol. Nutr. Food Res. 2011, 55:387-399.
187. Watzek N., Scherbl D., Schug M., Hengstler J.G., Baum M., Habermeyer M., Richling E., Eisenbrand G. Toxicokinetics of acrylamide in primary rat hepatocytes: coupling to glutathione is faster than conversion to glycidamide. Arch. Toxicol. 2013, 87(8):1545-1556. Epub 2013 Apr 9. 10.1007/s00204-013-1054-0.
188. Watzek N., Bohm N., Feld J., Scherbl D., Berger F., Merz K.H., Lampen A., Reemtsma T., Tannenbaum S.R., Skipper P.L., Baum M., Richling E., Eisenbrand G. N7-glycidamide-guanine DNA adduct formation by orally ingested acrylamide in rats: a dose-response study encompassing human diet-related exposure levels. Chem. Res. Toxicol. 2012, 25:381-390.
189. EFSA Results on acrylamide levels in food from monitoring years 2007-2009 and Exposure assessment. EFSA J. 2011, 9:48.
190. Chen L., Wang M., Villalta P.W., Hecht S.S. Liquid chromatography-electrospray ionization tandem mass spectrometry analysis of 7-ethylguanine in human liver DNA. Chem. Res. Toxicol. 2007, 20:1498-1502.
191. Cheng G., Wang M., Villalta P.W., Hecht S.S. Detection of 7-(2'-carboxyethyl)guanine but not 7-carboxymethylguanine in human liver DNA. Chem. Res. Toxicol. 2010, 23:1089-1096.
192. Wang M., Yu N., Chen L., Villalta P.W., Hochalter J.B., Hecht S.S. Identification of an acetaldehyde adduct in human liver DNA and quantitation as N2-ethyldeoxyguanosine. Chem. Res. Toxicol. 2006, 19:319-324.
193. Lutz W.K., Lutz R.W., Gaylor D.W., Conolly R.B. Dose-response relationship and extrapolation in toxicology. Mechanistic and statistical considerations. Regulatory Toxicology 2014, Springer-Verlag, Berlin, Heidelberg. 10.1007/978-3-642-35374-1_72. F.X. Reichl, M. Schwenk (Eds.).
194. Sanner T., Dybing E., Willems M.I., Kroese E.D. A simple method for quantitative risk assessment of non-threshold carcinogens based on the dose descriptor T25. Pharmacol. Toxicol. 2001, 88:331-341.
195. Yamada M., Matsui K., Sofuni T., Nohmi T. New tester strains of Salmonella typhimurium lacking O6-methylguanine DNA methyltransferases and highly sensitive to mutagenic alkylating agents. Mutat. Res. 1997, 381:15-24.
196. Lee S.F., Pervaiz S. Assessment of oxidative stress-induced DNA damage by immunoflourescent analysis of 8-oxodG. Methods Cell Biol. 2011, 103:99-113.
197. Cadet J., Douki T., Ravanat J.L. Measurement of oxidatively generated base damage in cellular DNA. Mutat. Res. 2011, 711:3-12.
198. Fabiani R., De Bartolomeo A., Rosignoli P., Morozzi G. Antioxidants prevent the lymphocyte DNA damage induced by PMA-stimulated monocytes. Nutr. Cancer 2001, 39:284-291.
199. Konopacka M., Rzeszowska-Wolny J. Antioxidant vitamins C, E and beta-carotene reduce DNA damage before as well as after gamma-ray irradiation of human lymphocytes in vitro. Mutat. Res. 2001, 491:1-7.
200. Johansson C., Moller P., Forchhammer L., Loft S., Godschalk R.W., Langie S.A., Lumeij S., Jones G.D., Kwok R.W., Azqueta A., Phillips D.H., Sozeri O., Routledge M.N., Charlton A.J., Riso P., Porrini M., Allione A., Matullo G., Palus J., Stepnik M., Collins A.R., Moller L. An ECVAG trial on assessment of oxidative damage to DNA measured by the comet assay. Mutagenesis 2010, 25:125-132.
201. Smith C.C., O'Donovan M.R., Martin E.A. hOGG1 recognizes oxidative damage using the comet assay with greater specificity than FPG or ENDOIII. Mutagenesis 2006, 21:185-190.
202. Collins A.R. Measuring oxidative damage to DNA and its repair with the comet assay. Biochim. Biophys. Acta 2014, 1840:794-800.
203. Willmore E., Frank A.J., Padget K., Tilby M.J., Austin C.A. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol. Pharmacol. 1998, 54:78-85.
204. Cowell I.G., Tilby M.J., Austin C.A. An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay. Mutagenesis 2011, 26:253-260.
205. Barth S.W., Briviba K., Watzl B., Jager N., Marko D., Esselen M. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats. Biotechnol. J. 2010, 5:321-327.
206. Subramanian D., Furbee C.S., Muller M.T. ICE bioassay. Isolating in vivo complexes of enzyme to DNA. Methods Mol. Biol. 2001, 95:137-147.
207. Meek M.E., Boobis A., Cote I., Dellarco V., Fotakis G., Munn S., Seed J., Vickers C. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J. Appl. Toxicol. 2014, 34:1-18.
208. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 2001, 34:146-152.
209. Clewell R.A., Sun B., Adeleye Y., Carmichael P., Efremenko A., McMullen P.D., Pendse S., Trask O.J., White A., Andersen M.E. Profiling dose-dependent activation of p53 mediated signaling pathways by chemicals with distinct mechanisms of DNA damage. Toxicol. Sci. 2014.
210. Hendriks G., Atallah M., Morolli B., Calleja F., Ras-Verloop N., Huijskens I., Raamsman M., van de Water B., Vrieling H. The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. Toxicol. Sci. 2012, 125:285-298.
211. Hendriks G., van de Water B., Schoonen W., Vrieling H. Cellular-signaling pathways unveil the carcinogenic potential of chemicals. J. Appl. Toxicol. 2013, 33:399-409.